Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Treatment of Hemorrhagic Cystitis

Initial Management and Resuscitation

  • The American College of Radiology recommends immediate hydration with forced diuresis to dilute toxic metabolites and reduce bladder toxicity, with a goal of 2-3 L in 24 hours 2
  • Continuous bladder irrigation with normal saline and clot evacuation should be initiated for active bleeding, as recommended by the European Association of Urology 1
  • Checking vital signs, hemoglobin, hematocrit, and coagulation parameters is essential to assess bleeding severity, according to the American College of Radiology 2
  • Performing urine analysis and culture to exclude infection as a contributing cause is crucial, as suggested by the European Association of Urology and the American College of Radiology 1, 2

Stepwise Treatment Algorithm

First-Line Medical Management

  • The European Association of Urology recommends non-steroidal anti-inflammatory drugs (NSAIDs) for pain control, with a strength of evidence rated as moderate 1, 2
  • Anticholinergic agents such as oxybutynin are recommended for urinary frequency, urgency, and bladder spasm symptoms, with a high level of evidence supporting their use 1, 2
  • Analgesics such as phenazopyridine are suggested for dysuria, with a low to moderate level of evidence 1

Second-Line Interventions

  • Endoscopic fulguration is recommended for bleeding control when conservative measures fail, with a high level of evidence supporting its use 1
  • Botulinum toxin A injection into the detrusor muscle is suggested when drug therapy proves ineffective, with a moderate level of evidence 1, 2

Prevention Strategies

  • The American Society of Clinical Oncology recommends mesna administration to bind the toxic metabolite acrolein in patients receiving cyclophosphamide or ifosfamide chemotherapy, with a high level of evidence supporting its use 2
  • For ifosfamide specifically, mesna should be given as IV bolus at 20% of the ifosfamide dose at time of administration, followed by oral mesna at 40% of the ifosfamide dose at 2 and 6 hours after each dose, as recommended by the American Society of Clinical Oncology 2
  • Patients who vomit within 2 hours of oral mesna must repeat the dose or receive IV mesna, with a moderate level of evidence supporting this recommendation 2
  • Monthly monitoring of urine for red blood cells is recommended for patients on cyclophosphamide, with a low to moderate level of evidence 2

Monitoring Requirements

  • The European Association of Urology recommends monitoring urine output and appearance continuously for signs of ongoing or worsening hematuria, with a high level of evidence supporting this recommendation 2
  • Assessing renal function regularly, particularly in patients with pre-existing renal impairment, is crucial, with a moderate level of evidence supporting this recommendation 2
  • Watching for signs of urinary tract infection is essential, as hemorrhagic cystitis predisposes to secondary infections, with a low to moderate level of evidence 2
  • For radiation cystitis, bladder bleeding may peak around 30 months post-treatment, after which prevalence rates typically return to baseline, with a moderate level of evidence supporting this finding 1